Navigation Links
Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Date:9/19/2011

ME-143. The second is a mitochondrial inhibitor program that includes lead candidate ME-344. The Company initiated a Phase I clinical trial of intravenous ME-143 in September 2011 and expects to submit an IND application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; go
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26
... (Nasdaq: VICL ),today is presenting expanded clinical ... Vaxfectin(R) adjuvant may be broadly,applicable in DNA- and ... P. Rolland, Pharm.D., Ph.D., Vical,s,Senior Vice President of ... 8, at the World Vaccine Congress (Lyon, France ...
... Texas, Oct. 7 The Texas Cardiac Arrhythmia,Institute ... selected as one of,only a few sites in ... for a new device to treat persistent atrial ... specializing in heart,rhythm disorders, is a partnership between ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2
(Date:8/21/2014)... 21, 2014 DMG Productions announces the ... to broadcast on Monday, August 25, 2014 at 7:00 ... , In this episode, Innovations will go behind-the-scenes ... and improves human performance. Audiences will be amazed by ... spaces by installing and providing access to real musical ...
(Date:8/21/2014)... 21, 2014 Taking its own advice ... of life, St. Louis’ Sound Mind Café recognized an ... revolutionized its online presence. Reorganized to highlight the personable ... website makes navigating for information and scheduling appointments a ... accessible menu-bar in jet black, the cafe’s new, revamped ...
(Date:8/21/2014)... Diego, CA (PRWEB) August 21, 2014 According ... the American Academy of Ophthalmology, environmental factors may outweigh genetics ... that about 42 percent of the world’s population is nearsighted, ... may be. , “This is an important finding in ... in Carlsbad. “Not only are we finding better ways to ...
(Date:8/21/2014)... Seattle, WA (PRWEB) August 21, 2014 ... Stephen Grant, found it hard to stay focused on ... midges and mosquitoes. The constant whine, slapping and continual ... began researching innovative methods to stay protected from insects ... a successful career in the Financial Services/Investment Banking Industry, ...
(Date:8/21/2014)... Denver marketing agency Webolutions® has ... Lung Association in Colorado’s 2014 Run the ‘Rocks ... a sponsor,” said Curt Huber, Chief Development Officer, American ... Lung Association in Colorado, “and we’re eager to see ... they’ve defined.” , Webolutions has also created and is ...
Breaking Medicine News(10 mins):Health News:Announcing New Episode Airing of Innovations on Monday August 25, 2014 via Discovery Channel 2Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3
... March 11 /PRNewswire-USNewswire/ -- Orthopaedic surgeon David Teuscher, ... (BOC) of the American Academy of Orthopaedic Surgeons ... Sands Expo Center in Las Vegas. He will also ... I will be one of the voices for our Board ...
... featured part of one of the fastest-growing online ... HCPLive.com today announced a traffic- and revenue-sharing partnership ... most widely read physician blogs. KevinMD.com, home of ... news, is written by Kevin Pho, MD, a ...
... Solutions and Services on the GSA Online Ordering System ... ... -- American TeleCare, Inc. (ATI), leader in the development and ... and services remain available to government agencies under new contracts ...
... March 11 JLL Patheon Holdings, LLC, an affiliate of ... commencing its previously announced offer for any and all of ... ("Patheon") that it does not already own at an offer ... Share, which is equivalent to approximately C $2.57 cash per ...
... Years of Personal Experience with Complex Rehab NeedsCHARLOTTE, N.C., ... has joined Alliance Seating & Mobility (ASM), ... companies. Fisher is an Assistive Technology Professional ... ) and provides power mobility solutions for pediatrics and ...
... study says, as Washington becomes 2nd state to legalize ... Concern about future suffering is the leading reason why ... Death With Dignity Act, according to an Oregon Health ... people who had requested physician aid in dying or ...
Cached Medicine News:Health News:David Teuscher, MD, Elected Secretary of Academy Board of Councilors 2Health News:KevinMD.com Joins the HCPLive.com Network 2Health News:American TeleCare, Inc. (ATI) Renews Agreements for its Telehealth Solutions with the Veterans Health Administration 2Health News:American TeleCare, Inc. (ATI) Renews Agreements for its Telehealth Solutions with the Veterans Health Administration 3Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 2Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 3Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 4Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 5Health News:JLL Commences Offer to Acquire Any and All Outstanding Shares of Patheon Inc. for U.S. $2.00 per Share in Cash 6Health News:Rehab Specialist, Michael Fisher, Joins Fast - Growing Alliance Seating & Mobility in North Carolina 2Health News:Fear of Pain Drives Requests for Assisted Death 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: